It was demonstrated that a gene or genes responsible for a whole spectrum of cardiovascular risk factors map to a limited segment of the centromeric region of rat chromosome 4. Recently, a spontaneous deletion in the gene for Cd36 that encodes a fatty acid transporter and is located directly at the peak of QTL linkages on chromosome 4 has been indirectly linked to the transmission of insulin resistance, defective fatty acid metabolism, and increased blood pressure. To directly test whether mutant Cd36 is a QTL that promotes clustering of multiple cardiovascular risk factors in the Spontaneously Hypertensive Rat (SHR), transgenic lines were derived that carry a wild type Cd36 transgene on the genetic background of the SHR strain harboring a deletion variant of Cd36. It was found that in SHR harboring the deletion variant of Cd36, transgenic expression of wild type Cd36 in modest amounts ameliorated defects in fatty acid metabolism, glucose tolerance, and insulin stimulated glucose uptake in muscle and fat tissue, however, exerted little or no effect on blood pressure. In conclusion, the current studies provided definitive evidence that mutant Cd36 is a QTL with major effects on fatty acid metabolism, insulin action, and glucose tolerance but have no effects on spontaneous hypertension in the SHR/NIH strains.
Keywords: CD36, Cardiovascular Risk Factor, Hypertensive Rat, INSULIN RESISTANCE, DYSLIPIDEMIA, HYPERTENSION, TRANSGENIC SHR
Synthesis and Biological Study of 3-Butyl-1-(2,6-dichlorophenyl)-1H-[1,2,4]triazol- 5(4H)-one Derivatives as Anti-hypertension Drugs
Letters in Drug Design & Discovery Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery (Discontinued) The Reservoir-Wave Paradigm: Potential Implications for Hypertension
Current Hypertension Reviews Incretin-Based Therapies in Patients with Type 2 Diabetes
Current Drug Therapy Imidazoline Receptor Agonists in Obesity-Related Hypertension: Therapeutic Targeting of the Sympathetic Nervous System
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) Renal Protective Effect of Metabolic Therapy in Patients with Coronary Artery Disease and Diabetes: From Bench to Bed Side
Current Pharmaceutical Design Predicting Esophageal Varices in Cirrhotic Hepatitis C Virus Patients Using Noninvasive Measurement of Insulin Resistance Variables
Endocrine, Metabolic & Immune Disorders - Drug Targets Are Calcium Channel Blockers First-Line Drugs for the Treatment of Hypertension and Cardiovascular Disease?
Current Hypertension Reviews Milk Fat Globule Epidermal Growth Factor VIII Signaling in Arterial Wall Remodeling
Current Vascular Pharmacology Mechanisms of the Penetration of Blood-Borne Substances into the Brain
Current Neuropharmacology Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews Effects of Endothelins on Cardiac and Vascular Cells: New Therapeutic Target for the Future?
Current Vascular Pharmacology Pulmonary Arterial Hypertension: Need to Treat
Inflammation & Allergy - Drug Targets (Discontinued) Aliskiren in Patients with Diabetes: A Systematic Review
Current Vascular Pharmacology Regulators of Platelet cAMP Levels: Clinical and Therapeutic Implications
Current Medicinal Chemistry Capsaicin Sensitive-Sensory Nerves and Blood Pressure Regulation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Relationships of Beta2- and Beta3--Adrenoceptor Polymorphisms with Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews Increased Salt Sensitivity in Obese Hypertension: Role of the Sympathetic Nervous System
Current Hypertension Reviews Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Current Vascular Pharmacology Biomechanical Stress-induced Signaling in Smooth Muscle Cells: An Update
Current Vascular Pharmacology